Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA public meeting

This article was originally published in The Tan Sheet

Executive Summary

FDA will hold a public meeting to discuss the creation of a private and public sector post-market safety network titled "Sentinel Network," the agency announces in the Jan. 18 Federal Register. The meeting, which will be held March 7 and 8, will identify the "obstacles to facilitators and incentives for developing the data collection and risk identification and analysis components." FDA says "such a network would integrate existing and planned efforts to collect, analyze and disseminate medical product safety information to health care practitioners and patients at the point-of-care." FDA announced a similar online initiative in February 2006 for a second generation Adverse Event Reporting System (1"The Tan Sheet," Feb. 20, 2006, p. 5)...

You may also be interested in...

Sentinel Network meeting update

FDA announces Feb. 15 it extended the registration deadline for a public meeting on the "Sentinel Network" to Feb. 28. FDA announced in January it scheduled a public meeting March 7 and 8 to discuss creating a private and public sector post-market network the agency says will integrate efforts to collect, analyze and disseminate product safety information to health care providers and patients (1"The Tan Sheet," Jan. 22, 2007, In Brief)...

AERs To Go Online: Drug Safety Budget Proposal Funds Web Version

FDA is proposing increased drug safety funding to launch its web-accessible, second-generation Adverse Event Reporting System

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts